SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following its latest update, which showcased substantial revenue growth and accelerating global expansion of its ANKTIVA cancer therapy, sparking community discussion around potential expedited regulatory approvals and a significant short squeeze opportunity amid high after-hours volatility.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is seeing intense trading and sharp declines despite broader energy sector rallies and surging crude oil prices driven by escalating Middle East tensions. The community is fiercely debating whether this extreme volatility stems from active dilution and market manipulation or is a massive shakeout positioning the low-float stock for a potential short squeeze, reminiscent of its historical explosive movements during geopolitical events.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending following its recent earnings report, which delivered a narrow beat and generally in-line guidance, sparking a heated community debate between those who view it as a leading cybersecurity platform poised to benefit from AI and rising geopolitical tensions, and others who contend its valuation remains excessively high despite analyst upgrades.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending following mixed reactions to its Q4 '26 earnings report, which saw a beat on revenue and EPS along with a $400M share repurchase program, yet offered weaker-than-expected FY2027 guidance. The community is divided between those buying the dip, citing AI integration and persistent buyout rumors, and bears concerned about slowing growth and the impact of AI competition on software companies.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a strong earnings beat and robust cash position, yet community discussion is overwhelmingly dominated by frustration over CEO Peter Greenleaf's continued lack of transparency regarding AUR200's clinical trial indications, fueling speculation of an imminent buyout amidst accusations of mismanagement.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics Inc. is trending following its transformative acquisition of Covelya Group, significantly expanding its global footprint in subsea technology and positioning it as a major supplier for defense and commercial sectors. The community is actively discussing potential short-term share dilution from a public offering against robust long-term growth potential and strategic partnerships within the burgeoning underwater robotics sector.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing significant market interest and trading volume amid escalating geopolitical tensions, with the community speculating on its tactical drone systems' role in modern warfare and the potential for increased defense contracts. This surge is further bolstered by analyst optimism and a new partnership with Allen Control Systems to advance counter-drone capabilities, fueling discussions about a potential short squeeze.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as escalating Middle East tensions halt Qatar's LNG production and disrupt the Strait of Hormuz, driving global natural gas prices dramatically higher. This geopolitical "perfect storm," combined with a strong earnings beat and a favorable legal outcome against Shell, positions the company as a key beneficiary, fueling community discussion around potential short squeezes and its undervalued status.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors balance the potential boost to its defense segment from geopolitical tensions with ongoing commercial recovery efforts, amidst community debate over the stock's subdued reaction despite reports of increasing aircraft deliveries and new orders.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd (SE) is trending after its earnings report showed revenue beating expectations while EPS missed, sparking an initial sharp sell-off. The community is actively discussing whether the market's reaction was overdone, with many noting robust top-line growth across its e-commerce and digital financial services segments, leading to a significant recovery as buyers stepped in.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

XOMA Royalty Corporation (XOMA) and LAVA Therapeutics NV (LVTX) announced on Friday that they have agreed to amend their previous share purchase agreement and lowered the initial cash consideration to be received by LAVA shareholders.As per the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.xoma.com/news-events/press-releases/detail/487/xoma-royalty-and-lava-therapeutics-announce-amendment-to">amended deal</a>, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. Shareholders will also receive a contingent value right (CVR) representing the right to certain cash payments, the companies said.This includes the previously announced rights to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out-license or sale of LAVA’s unpartnered programs, in addition to a new right to receive up to approximately $0.23 per CVR.LAVA and XOMA Royalty also agreed to amend LAVA’s minimum net-cash closing condition to be $24.5 million, compared to the previous minimum net-cash closing condition of $31.5 million. The amended agreement is in light of the most recent estimates of LAVA’s expected cash balance at closing, among other factors, the companies said. The proposed acquisition is expected to close in the fourth quarter of 2025, as announced previously.LAVA said that it expects to convene a meeting of shareholders to approve matters related to the deal with XOMA Royalty on November 7, after <a href="https://stocktwits.com/news-articles/markets/equity/lava-therapeutics-stock-drops-after-company-cancels-shareholder-meeting/chDD4XlR3BN">postponing</a> it from its previous date of September 30.Last month, LAVA canceled its shareholder meeting to consider and approve matters related to the proposed transaction with XOMA. XOMA first announced that it would acquire LAVA in August.<a href="https://stocktwits.com/symbol/LVTX">LAVA shares</a> fell 3% on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around LVTX stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:588/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_2_25_55_PM_png_0c5aac6302.webp" alt="LVTX's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="63"><figcaption>LVTX's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>While LVTX shares have gained 56% this year, XOMA stock has risen 30%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.

Equity

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.


Shares of LAVA Therapeutics (LVTX) declined 8% in the pre-market session on Tuesday after the company canceled the Extraordinary General Meeting of shareholders scheduled to occur today.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/30/3158434/0/en/LAVA-Therapeutics-to-Move-Extraordinary-General-Meeting-to-Early-November-2025.html">said</a> that it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation (XOMA). XOMA announced in August that it will acquire LAVA for between $1.16 and $1.24 per share in cash, in addition to a contingent value right per share. The deal is expected to close in the fourth quarter (Q4) of 2025.The company said on Tuesday that it is canceling the meeting to continue discussions with XOMA concerning its estimated cash forecast and the consideration payable to the company’s shareholders in the transaction.LAVA also noted that both parties remain committed to completing the transaction by the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LVTX">LVTX stock</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.“We are committed to closing this transaction and look forward to working collaboratively with the LAVA team to further define LAVA’s cash forecast in an effort to close this transaction in an expeditious manner,” said XOMA CEO Owen Hughes.LAVA said on Tuesday that it expects to reconvene the shareholder meeting by early November. The date will be ascertained at a later date, and shareholders who have voted will have to cast their votes again on the matters proposed, it added.LVTX stock is up 69% this year but down approximately 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/chainlink-swift-advance-blockchain-integration-for-ubs-tokenized-funds/chDD4dRR3Bj">Chainlink, Swift Advance Blockchain Integration For UBS Tokenized Funds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting

The firm stated it canceled the meeting to consider and approve certain matters related to its proposed transaction with XOMA Royalty Corporation. 

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

LVTX
LAVA Therapeutics NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LVTX News

LVTXLAVA Therapeutics NV